Home
HelpTest ID GASCA Saccharomyces cerevisiae Antibody, IgG, Serum
Useful For
Helping clinicians distinguish between ulcerative colitis and Crohn's disease in patients suspected of having inflammatory bowel disease
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Reporting Name
Saccharomyces cerevisiae Ab, IgG, SSpecimen Type
SerumContainer/Tube:
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 0.50 mL
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 21 days |
| Frozen | 21 days |
Clinical Information
Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn's disease (CD), which produce inflammation of the large or small intestines.(1) The diagnoses of both diseases are based on clinical features, radiographic findings, colonoscopy, mucosal biopsy histology, and, in some cases, operative findings and resected bowel pathology and histology.
Patients with IBD have also been shown to have antibodies in serum that help distinguish between CD and UC.(2) Patients with UC often have measurable neutrophil-specific antibodies (NSA) that react with as yet uncharacterized target antigens in human neutrophils; whereas patients with CD often have measurable antibodies of the IgA and/or IgG isotypes that react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.
Reference Values
Negative: ≤20.0 U
Equivocal: 20.1-24.9 U
Weakly positive: 25.0-34.9 U
Positive: ≥35.0 U
Reference values apply to all ages.
Cautions
IBDP / Inflammatory Bowel Disease Serology Panel, Serum is useful as an adjunct in the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD), but should not be relied upon exclusively to establish the diagnosis or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophil-specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).
Measurement of ASCA and NSA are not useful to determine the extent of disease in patients with inflammatory bowel disease or to determine the response to disease-specific therapy including surgical resection of diseased intestine.
Day(s) Performed
Monday through Friday; 5 p.m.
Report Available
Same day/1 dayPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86671